Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice (Q42244962)

19 October 2017

title

Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice (English)

1 reference

Japanese encephalitis virus

19 October 2017

main subject

0 references

Japanese encephalitis

1 reference

1 reference

tick-borne encephalitis virus

object named as

tick-borne encephalitis virus

1 reference

Cheng-Feng Qin

0 references

Yong-Qiang Deng

1 reference

19 October 2017

Xiao-Feng Li

1 reference

19 October 2017

Hong-Jiang Wang

1 reference

19 October 2017

Qing Ye

1 reference

19 October 2017

Shi-Hua Li

1 reference

19 October 2017

Hui Zhao

1 reference

19 October 2017

Yan-Peng Xu

1 reference

19 October 2017

Jie Ma

1 reference

19 October 2017

E-De Qin

1 reference

19 October 2017

language of work or name

English

0 references

publication date

4 January 2014

1 reference

19 October 2017

1 reference

19 October 2017

1 reference

19 October 2017

1 reference

19 October 2017

page(s)

949-956

1 reference

Specific clinical and epidemiological features of tick-borne encephalitis in Western Siberia

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-Borne Encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Tick-borne encephalitis 2010: Epidemiology, risk areas, and virus strains in Europe and Asia—An overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Tick-borne encephalitis virus - a review of an emerging zoonosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Tick-borne encephalitis vaccines: past and present

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Field effectiveness of vaccination against tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN "NEW" in children: results of post-marketing surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Two severe cases of tick-borne encephalitis despite complete active vaccination--the significance of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

The Golden Agers and Tick-borne encephalitis. Conference report and position paper of the International Scientific Working Group on Tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Tick-borne encephalitis after vaccination: Vaccine failure or misdiagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Vaccine failures after active immunisation against tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area--impact on current recommendations for immunization of high-risk groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Rational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Complete genome sequence analysis of tick-borne encephalitis viruses isolated in northeastern China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.12.050

1 reference

19 October 2017

1 reference